Among SGLT2 inhibitor users, the proportions of patients experiencing dialysis, MACE, HF, and MI were 5% (95% CI, 3–7%), 4% (3–5%), 5% (0–13%), and 1% (0–2%), respectively. The gene discussed is SLC5A2; the disease is hydrops fetalis.